ENTITY
Venus MedTech

Venus MedTech (2500 HK)

109
Analysis
Health CareChina
Venus MedTech (HangZhou) Inc. develops and sells cardiovascular devices. The Company offers products including aorta, compression loading and conveying systems, and pulmonary artery. Venus MedTech (HangZhou) markets its products throughout China.
more
Refresh
20 Mar 2020 12:21

InnoCare (诺诚健华) IPO Trading: At the Mercy of Retail Flipping

InnoCare, a China-based biotech company founded by a famous scientist, raised USD 270 million at HKD 8.95 per share. In this insight, we will cover...

Logo
400 Views
Share
bullishPeijia Medical
18 Feb 2020 10:34

Peijia Medical (沛嘉医疗) Pre-IPO: Reminiscence of Venus Medtech?

Peijia Medical is a leading domestic player in the transcatheter valve therapeutic medical device market and the neurointerventional procedural...

Logo
1.2k Views
Share
16 Jan 2020 14:57

2019 Hong Kong IPO Analytics: How Did Insti and Retail Coverage Impact Deal Performance

Since the inception of our IPO research in 2015, the Aequitas Research team has covered over 452 IPOs, which raised over US$100m each, across the...

Logo
512 Views
Share
bullishJiumaojiu
14 Jan 2020 17:44

Jiumaojiu (九毛九) Trading - Off to a Great Start with 638x Oversubscription

Jiumaojiu (9922 HK) raised about US$283m at HK$6.60 per share, the top end of its IPO price range. We have previously covered the IPO...

Share
bullishVenus MedTech
09 Dec 2019 17:08

Venus Medtech (启明医疗) IPO Trading: Allocation and Buy-Level

Venus Medtech, the dominant player in the heart valve replacement segment in China, raised USD 311 million at HKD 33.0 per share. In this insight,...

Logo
497 Views
Share
x